Central nervous system ischemia

Platelets

Volumn , Issue , 2007, Pages 657-683

  Zoppo, Gregory J del ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884749632     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50798-9     Document Type: Chapter

References (306)

1. Denny-Brown D. Recurrent cerebrovascular episodes. Arch Neurol 1960, 2:194-210.
2. Russell R.W.R. Observations on the retinal blood vessels in monocular blindness. Lancet 1961, 2:1422-1428.
3. Hollenhorst R.W. Vascular status of patients who have cholesterol emboli in the retina. Am J Ophthalmol 1966, 77:1159-1165.
4. Barnett H.J.M. The pathophysiology of transient cerebral ischemic attacks: Therapy with platelet antiaggregants. Med Clin North Am 1979, 63:649-679.
5. Barnett H.J.M. Delayed cerebral ischemic episodes distal to occlusion of major cerebral arteries. Neurology 1978, 28:769.
6. del Zoppo G.J., Poecm K., Pessin M.S., et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992, 32:78-86.
7. Fieschi C., Argentino C, .Lenzi G.L., et al. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989, 91:311-321.
8. del Zoppo G.J., Higashida R.T., Furlan A.J., et al. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998, 29:4-11.
9. Delanty N., Vaughan C.J. Vascular effects of statins in stroke. Stroke 1997, 28:2315-2320.
10. Laufs U., Gertz K., Huang P., et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000, 31:2442-2449.
11. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996, 335:1001-1009.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study 4S. Lancet 1994, 344:1383-1389.
13. Greisenegger S., Mullner M., Tentschert S., et al. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004, 221:5-10.
14. Marti-Fabregas J., Gomis M., Arboix A., et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004, 35:1117-1121.
15. Stroke Council AHAASA. Statins after ischemic stroke and transient ischemic attack: An advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke 2004, 35:1023.
16. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993, 362:801-809.
17. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999, 340:115-126.
18. Mohr J.P., Caplan L.R., Melski J.W., et al. The Harvard Cooperative Stroke Registry: A prospective registry of patients hospitalized with stroke. Neurology 1978, 28:754-762.
19. Sacco R.L., Wolf P.A., Kannel W.B., et al. Survival and recurrence following stroke: The Framingham Study. Stroke 1982, 13:290-295.
20. Mohr J.P., Barnett H.J.M. Classification of ischemic strokes. Stroke: Pathophysiology, diagnosis and management 1986, Vol. 1:281-291. Churchill Livingstone, New York. H.J. M. Barnett, B.M. Stein, J.P. Mohr (Eds.).
21. Jones E.F., Calafiore P., Donnan G.A., et al. Evidence that patent foramen ovale is not a risk factor for cerebral ischemia in the elderly. Am J Cardiol 1994, 74:596-599.
22. Cujec B., Mainra R., Johnson D.H. Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol 1999, 15:57-64.
23. Rodriguez C.J., Homma S., Sacco R.L., et al. Race-ethnic differences in patent foramen ovale, atrial septal aneurysm, and right atrial anatomy among ischemic stroke patients. Stroke 2003, 34:2097-2102.
24. Solis O.J., Roberson G.R., Taveras J.M., et al. Cerebral angiography in acute cerebral infarction. Revist Interam Radiol 1977, 2:19-25.
25. rt-PA Acute Stroke Study Group. An open safety/effi-cacy trial of rt-PA in acute thromboembolic stroke: Final report. Stroke 1991, 22:153.
26. Irino T., Taneda M., Minami T. Angiographic manifestations in post-recanalized cerebral infarction. Neurology 1977, 27:471-475.
27. Marshall J. The natural history of transient ischemic cerebrovascular attacks. Q J Med 1964, 33:309-324.
28. Wolf P.A., Kannel W.B., McGee D.L., et al. Duration of atrial fibrillation and imminence of stroke: The Framingham Study. Stroke 1983, 14:664-667.
29. Wolf P.A., Kannel W.B., McGee D.L. Prevention of ischemic stroke: Risk factors. Stroke: Pathophysiology, diagnosis, and management 1986, 983. Churchill- Livingstone, New York. H.J. M. Barnett, J.P. Mohr, B.M. Stein (Eds.).
30. Whisnant J.P., Matsumoto N., Elveback L.R. Transient cerebral ischemic attacks in a community, Rochester, Minnesota, 1955 through 1969. Mayo Clin Proc 1973, 48:194-198.
31. Caplan L.R. Are terms such as completed stroke or RIND of continued usefulness?. Stroke 1983, 14:431-433.
32. Schmidt E.V., Smirnov V.E., Ryabova V.S. Results of the seven-year prospective study of stroke patients. Stroke 1988, 19:942-949.
33. van Kooten F., Ciabattoni G., Patrono C., et al. Evidence for episodic platelet activation in acute ischemic stroke. Stroke 1994, 25:278-281.
34. van Kooten F., Ciabattoni G., Koudstaal P.J., et al. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke 1999, 30:546-549.
35. Spencer M.P., Thomas G.I., Nicholls S.C., et al. Detection of middle cerebral artery emboli during carotid endarterectomy using transcranial Doppler sonography. Stroke 1990, 21:415-423.
36. Markus H.S., Thomson N., Brown M.M. Asymptomatic cerebral embolic signals in symptomatic and asymptomatic carotid artery disease. Brain 1995, 118:1005-1011.
37. Tong D., Albers G. Transcranial Doppler-detected microemboli in patients with acute stroke. Stroke 1995, 26:1588-1592.
38. Sliwka U., Job F.P., Wissuwa D., et al. Occurrence of transcranial Doppler high intensity signals in patients with potential cardiac source of embolism. Stroke 1996, 26:2067-2070.
39. Sliwka U., Lingnau A., Stohlmann W.-D, et al. Prevalence and time course of microembolic signals in patients with acute stroke. Stroke 1997, 27:1844-1849.
40. Batista P., Oliveira V., Ferro J.M. The detection of microembolic signals in patients at risk of recurrent cardioembolic stroke: Possible therapeutic relevance. Cerebrovasc Dis 1999, 9:314-319.
41. Wityk R.J., Pessin M.S., Kaplan R.F., et al. Serial assessment of acute stroke using the NIH stroke scale. Stroke 1994, 25:362-365.
42. Dougherty J.H., Levy D.E., Weksler B.B. Platelet activation in acute cerebral ischemia. Lancet 1977, 3:821-824.
43. Mettinger K.L., Nyman D., Kjellin K.-G., et al. Factor VIII related antigen, anti-thrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease. J Neurol Sci 1979, 41:31-38.
44. deBoer A.C. Plasma beta-thromboglobulin and serum fragment E in acute partial stroke. Br J Haematol 1982, 50:327-344.
45. Cella G., Zahavi J., de Haas H.A., et al. β-thromboglobulin, platelet production time, and platelet function in vascular disease. Br J Haematol 1979, 43:127-136.
46. Feinberg W.M., Bruck D.C., Ring M.E., et al. Hemostatic markers in acute stroke. Stroke 1989, 20:592-597.
47. Feinberg W.M., Bruck D.C. Time course of platelet activation following acute ischemic stroke. J Stroke Cerebrovasc Dis 1991, 1:124-128.
48. Feinberg W.M., Pearce L.A., Hart R.G., et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999, 30:2547-2553.
49. Fisher M., Zipser R. Increased excretion of immunoreactive thromboxane B2 in cerebral ischemia. Stroke 1985, 16:10-14.
50. Zeller J.A., Tschoepe D., Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999, 81:373-377.
51. Akopov S., Sercombe R., Seylaz J. Cerebrovascular reactivity: Role of endothelium/platelet/leukocyte interactions. Cerebrovasc Brain Metab Rev 1996, 8:11-94.
52. Weksler B.B. Hematologic disorders and ischemic stroke. Curr Opin Neurol 1995, 8:38-44.
53. Uchiyama S., Takeuchi M., Osawa M., et al. Platelet function in thrombotic cerebrovascular disorders. Stroke 1983, 14:511-517.
54. Pramsohler B., Lupattelli G., Scholz H., et al. Platelet scintigraphy and survival in juvenile stroke patients. Prog Clin Biol Res 1990, 355:71-80.
55. Uchiyama S., Yamazaki M., Hara Y., et al. Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke. Semin Thromb Hemost 1997, 23:535-541.
56. Harker L.A., Slichter S.J. Arterial and venous thromboembolism. Diath Haemorrh 1974, 31:188-203.
57. Sinzinger H., Silberbauer K., Fitscha P., et al. Wertigkeit des Nachweises atherosklerotischer Lasionen mit markierten autologen Thrombozyten. Acta Med Aust 1982, 9:181-184.
58. Iwamoto T., Kubo H., Takasaki M. Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease. Stroke 1995, 26:52-56.
59. Hamann G.F., Okada Y., del Zoppo G.J Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab, 1996, 16:1373-1378.
60. Legrand C., Woimant F., Haguenau M., et al. Platelet surface glycoprotein changes in patients with cerebral ischemia. Nouvelle Revue Francaise d'hematology 1991, 33:497-499.
61. Konstantopoulos K., Grotta J.C., Sills C., et al. Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost 1995, 74:1329-1334.
62. Shah A.B., Beamer N., Coull B.M. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke 1985, 16:643-647.
63. de Boer A.C., Turpie A.G., Butt R.W., et al. Plasma beta thromboglobulin and serum fragment E in acute partial stroke. Br J Haematol 1982, 50:327-334.
64. Grau A.J., Boddy A.W., Dukovic D.A., et al. CAPRIE Investigators. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004, 35:1147-1152.
65. Meiklejohn D.J., Vickers M.A., Morrison E.R., et al. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001, 112:621-631.
66. Minamino T., Kitakaze M., Sanada S., et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: Role of nitric oxide. Br J Haematol 1998, 98:1721-1727.
67. Lee Y.J., Jy W., Horstman L.L., et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1994, 72:295-304.
68. Geiser T., Sturzenegger M., Genewein U., et al. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke 1998, 29:1770-1777.
69. van Kooten F., Ciabattoni G., Patrono C., et al. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. Stroke 1997, 28:1557-1563.
70. Yip H.K., Chen S.S., Liu J.S., et al. Serial changes in platelet activation in patients after ischemic stroke: Role of pharmacodynamic modulation. Stroke 2005, 35:1683-1687.
71. Barnett H.J.M. Medical treatment of transient ischemia. Cerebral blood flow physiologic and clinical aspects 1987, 595. McGraw-Hill, New York. J.H. Wood (Ed.).
72. Lane D.A., Wolff S., Ireland H., et al. Activation of coagulation and fibrinolytic systems following stroke. Br J Haematol 1983, 53:655-658.
73. Reiner A.P., Siscovick D.S., Rosendaal F.R. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001, 85:584-595.
74. Manca G., Parenti G., Bellina R., et al. 111Inplatelet scintigraphy for the noninvasive detection of carotid plaque thrombosis. Stroke 2001, 32:719-727.
75. Fisher M., Sandler R., Weiner J.M. Delayed cerebral ischemia following arteriography. Stroke 1985, 16:431-434.
76. Schror K., Braun M. Platelets as a source of vasoactive mediators. Stroke 1990, 21(12 Suppl.):IV32-IV35.
77. Antiplatelet Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J 2002, 324:71-86.
78. Gubitz G., Sandercock P., Counsell C. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews computer file 2000, [2.], CD000029.
79. Nag S., Robertson D.M. Gross pathologic anatomic. Cerebral blood flow 1987, 59-74. McGraw-Hill, New York. J.H. Wood (Ed.).
80. Frijns C.J., Kappelle L.J., van Gijn J., et al. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke 1997, 28:2214-2218.
81. Mondy J.S., Lindner V., Miyashiro J.K., et al. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo. Circ Res 1997, 81:320-327.
82. Myllarniemi M., Calderon L., Lemstrom K., et al. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J 1997, 11:1119-1126.
83. Spence J.D., Perkins D.G., Kline R.L., et al. Hemodynamic modification of aortic atherosclerosis. Effects of propranolol versus hydralazine in hypertensive hyperlipidemic rabbits. Atherosclerosis 1984, 50:325-333.
84. Steinman D.A., Poepping T.L., Tambasco M., et al. Flow patterns at the stenosed carotid bifurcation: Effect of concentric versus eccentric stenosis. Ann Biomed Engineering 2000, 28:415-423.
85. Kawasaki T., Dewerchin M., Lijnen H.R., et al. Mouse carotid artery ligation induces platelet-leukocytedependent luminal fibrin, required for neointima development. Circ Res 2001, 88:159-166.
86. Caplan L.R., Tettenborn B. Embolism in the posterior circulation. Vertebrobasilar arterial disease 1992, 52-65. Quality Medical Publishing, St. Louis. R. Bergeur, L.R. Caplan (Eds.).
87. Fisher C.M. The arterial lesions underlying lacunes. Acta Neuropathol Berl 1969, 12:1-15.
88. Potthast K., Erdonmez G., Schnelke C., et al. Origin and appearance of HITS induced by prosthetic heart valves: An in vitro study. Int J Artif Organs 2000, 23:441-445.
89. Rambod E., Beizaie M., Shusser M., et al. A physical model describing the mechanism for formation of gas microbubbles in patients with mitral mechanical heart valves. Ann Biomed Engineering 1999, 27:774-792.
90. Markus H.S., Droste D.W., Kaps M., et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis CARESS. Trial. Circulation 2005, 111:2233-2240.
91. Kealy W.F. Atheroembolism. J Clin Pathol 1978, 31:984-989.
92. Lammie G.A., Sandercock P.A., Dennis M.S. Recently occluded intracranial and extracranial carotid arteries. Relevance of the unstable atherosclerotic plaque. Stroke 1999, 30:1319-1325.
93. Jeynes B.J. An assessment of the extent and distribution of experimentally induced cerebral atheroembolic vascular occlusions and infarcts. Artery 1986, 14:35-42.
94. Fieschi C., Battistini N., Volanto F., et al. Animal model of TIA: An experimental study with intracarotid ADP infusion in rabbits. Stroke 1975, 6:617-621.
95. Furlow T.W., Bass N.H. Stroke in rats produced by carotid injection of sodium arachidonate. Science 1975, 197:658-660.
96. Passero S., Battistini N., Fieschi C. Platelet embolism in rabbit brain. Stroke 1981, 12:781-786.
97. del Zoppo G.J. Relevance of focal cerebral ischemia models. Experience with fibrinolytic agents. Stroke 1990, 21:IV.
98. Roux S., Carteaux J.P., Hess P., et al. Experimental carotid thrombosis in the guinea pig. Thromb Haemost 1994, 71:252-256.
99. Golino P., Ambrosio G., Pascucci I., et al. Experimental carotid stenosis and endothelial injury in the rabbit: An in vivo model to study intravascular platelet aggregation. Thromb Haemost 1992, 67:302-305.
100. Ito T., Matsuno H., Kozawa O., et al. Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis. Thromb Res 1999, 95:49-61.
101. Matsuno H., Kozawa O., Niwa M., et al. Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by t-PA in the injured carotid artery of the hamster. J Cardiovasc Pharmacol 1998, 32:191-197.
102. Quaknine-Orlando B., Samama C.M., Riou B., et al. Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Anesthesiology 1999, 90:1454-1461.
103. Kessler C., Kelly A.B., Suggs W.D., et al. Induction of transient neurological dysfunction in baboons by platelet microemboli. Stroke 1992, 23:697-702.
104. Dietrich W.D., Prado R., Halley M., et al. Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats. J Neuropathol Exp Neurol 1993, 52:351-360.
105. Dietrich W.D., Dewanjee S., Prado R., et al. Transient platelet accumulation in the rat brain after common carotid artery thrombosis. An 111-In-labeled platelet study. Stroke 1993, 24:1534-1540.
106. Akopov S., Ghazarian A., Gabrielian E. Effects of nimodipine and nicergoline on cerebrovascular injuries induced by activation of platelets and leukocytes in vivo. Arch Int Pharmacodyn Ther 1992, 318:66-75.
107. Akopov S.E., Sercombe R., Seylaz J. Endothelial dysfunction in cerebral vessels following carotid artery infusion of phorbol ester in rabbits: The role of polymorphonuclear leukocytes. J Cereb Blood Flow Metab 1994, 14:1078-1087.
108. Okada Y., Copeland B.R., Mori E., et al. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994, 25:202-211.
109. del Zoppo G.J., Copeland B.R., Harker L.A., et al. Experimental acute thrombotic stroke in baboons. Stroke 1986, 17:1254-1265.
110. 3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000, 31:1402-1410.
111. del Zoppo G.J., Schmid-Schönbein G.W., Mori E., et al. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991, 22:1276-1284.
112. Choudhri T.F., Hoh B.L., Zerwes H.G, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptormediated platelet aggregation. J Clin Invest 1998, 102:1301-1310.
113. Moriguchi A., Maeda M., Mihara K., et al. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: Comparison with triofi ban. J Cereb Blood Flow Metab 2005, 25:75-86.
114. Moriguchi A., Mihara K., Aoki T., et al. Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig. Eur J Pharmacol 2004, 498:179-188.
115. Garcia J.H., Liu K.F., Yoshida Y., et al. Influx of leukocytes and platelets in an evolving brain infarct Wistar rat. Am J Pathol 1994, 144:188-199.
116. Rosenblum W.I. Control of brain microcirculation by endothelium. Keio J Med 1990, 39:137-141.
117. Mayhan W.G., Faraci F.M. Cerebral vasoconstrictor responses to serotonin during chronic hypertension. Hypertension 1990, 15:872-876.
118. Mayhan W.G., Faraci F.M., Heistad D.D. Responses of cerebral arterioles to adenosine 5□CE-diphosphate, serotonin, and the thromboxane analogue U-46619 during chronic hypertension. Hypertension 1988, 12:556-561.
119. Heistad D.D., Breese K., Armstrong M.L. Cerebral vasoconstrictor responses to serotonin after dietary treatment of atherosclerosis: Implications for transient ischemic attacks. Stroke 1987, 18:1068-1073.
120. Mayhan W.G., Faraci F.M., Heistad D.D. Impairment of endothelium-dependent responses of cerebral arterioles in chronic hypertension. Am J Physiol 1987, 253:H1435-H1440.
121. Sobey C.G., Faraci F.M., Piegors D.J., et al. Effect of short-term regression of atherosclerosis on reactivity of carotid and retinal arteries. Stroke 1996, 27:927-933.
122. Joseph R., Tsering C., Grunfeld S., et al. Platelet secretory products may contribute to neuronal injury. Stroke 1991, 22:1448-1451.
123. Joseph R., Tsering C., Welch K.M. Study of platelet-mediated neurotoxicity in rat brain. Stroke 1992, 23:394-398.
124. Joseph R., Tsering C., Grunfeld S., et al. Further studies on platelet-mediated neurotoxicity. Brain Res, 1992, 577:268-275.
125. Aliprandi A., Longoni M., Stanzani L., et al. Increased plasma glutamate in stroke patients might be linked to altered platelet release and uptake. J Cereb Blood Flow Metab 2005, 25:513-519.
126. Okada Y., Copeland B.R., Fitridge R., et al. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 1994, 25:1847-1854.
127. del Zoppo G.J., Yu J.-Q., Copeland B.R., et al. Tissue factor localization in non-human primate cerebral tissue. Thromb Haemost 1992, 68:642-647.
128. Thomas W.S., Mori E., Copeland B.R., et al. Tissue factor contributes to microvascular defects following cerebral ischemia. Stroke 1993, 24:847-853.
129. Mousa S.A., DeGrado W.F., Mu D.X., et al. Oral antiplatelet, anthithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist. Circulation 1996, 93:537-543.
130. Rebello S.S., Driscoll E.M., Lucchesi B.R. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke 1997, 289:1789-1796.
131. Mousa S.A., Mu D.X., Lucchesi B.R. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs. Stroke 1997, 28:830-835.
132. Rote W.E., Nedelman M.A., Mu D.X., et al. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys. Stroke 1994, 25:1223-1232.
133. Frenette P.S., Denis C.V., Weiss L., et al. Pselectin glycoprotein ligand 1 (PSGL-1). is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000, 191:1413-1422.
134. Forlow S.B., McEver R.P., Nollert M.U. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 2000, 95:1317-1323.
135. Connolly E.S., Winfree C.J., Prestigiacomo C.J., et al. Exacerbation of cerebral injury in mice that express the P-selectin gene: Identification of P-selectin blockade as a new target for the treatment of stroke. Circ Res, 1997, 81:304-310.
136. Vasthare U.S., Heinel L.A., Rosenwasser R.H., et al. Leukocyte involvement in cerebral ischemia and reperfusion injury. Surg Neurol 1990, 33:261-265.
137. Chopp M., Zhang R.L., Chen H., et al. Post ischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke 1994, 25:869-875.
138. Walder C.E., Green S.P., Darbonne W.C., et al. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidate. Stroke 1997, 28:2252-2258.
139. Carter A.M., Catto A.J., Bamford J.M, et al. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol 1998, 18:1124-1131.
140. Baker R.I., Eikelboom J., Lofthouse E., et al. Platelet glycoprotein Ib alpha Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood 2001, 98:36-40.
141. Frank M.B., Reiner A.P., Schwartz S.M., et al. The Kozak sequence polymorphism of platelet glycoprotein Iba alpha and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood 2001, 97:875-879.
142. Reiner A.P., Kumar P.N., Schwartz S.M., et al. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000, 31:1628-1633.
143. Carter A.M., Catto A.J., Bamford J.M., et al. Association of the platelet glycoprotein IIb HPA-3 polymorphism with survival after acute ischemic stroke. Stroke 1999, 30:2606-2611.
144. Hsieh K., Funk M., Schillinger M., et al. Vienna Stroke Registry. Impact of the platelet glycoprotein Ib alpha Kozak polymorphism on the risk of ischemic cerebrovascular events: A case-control study. Blood Coagul Fibrinolysis 2004, 15:469-473.
145. Bogousslavsky J., Van Melle G., Regli F. The Lausanne Stroke Registry: Analysis of 1000 consecutive patients with first stroke. Stroke 1988, 19:1083-1092.
146. Foulkes M.A., Wolf P.A., Price T.R., et al. The stroke data bank: Design, methods, and baseline characteristics. Stroke 1988, 19:547-554.
147. del Zoppo G.J., Mori E. Hematologic causes of intracerebral hemorrhage and their treatment. Neurosurg Clin North Am 1992, Vol. 33:637-658. Saunders, Philadelphia. H.H. Batjer (Ed.).
148. Figueroa M., Gehlsen J., Hammond D., et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993, 328:1226-1229.
149. McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Eng J Med 2001, 344:1402-1403.
150. Matthay K.K., Koerper M.A., Ablin A.R. Intracranial hemorrhage in congenital factor VII deficiency. J Pediatr 1979, 94:413-415.
151. Ragni M.V., Lewis J.H., Spero J.A., et al. Factor VII deficiency. Am J Hematol 1981, 10:79-88.
152. Petri M., Ellman L., Carey R. Acquired factor XIII deficiency with chronic myelomonocytic leukemia. Ann Intern Med 1983, 99:638-639.
153. Fisher M., Adams R.D. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. Neuropathol Exp Neurol 1951, 10:92-94.
154. Fisher C.M., Adams R.D. Observations on brain embolism with special reference to hemorrhage infarction. The heart and stroke. Exploring mutual cerebrovascular and cardiovascular issues 1987, 17-36. Springer-Verlag, New York. A.J. Furlan (Ed.).
155. Jörgensen L., Torvik A. Ischaemic cerebrovascular diseases in an autopsy series. Part 2. Prevalence, location, pathogenesis, and clinical course of cerebral infarcts. J Neurol Sci 1969, 9:285-320.
156. Lodder J., Krijne-Kubat B., Broekman J. Cerebral hemorrhagic infarction at autopsy: Cardiac embolic cause and the relationship to the cause of death. Stroke 1986, 17:626-629.
157. Lodder J. CT-detected hemorrhagic infarction: Relation with the size of the infarct, and the presence of midline shift. Acta Neurol Scand 1984, 70:329-335.
158. Yamaguchi T., Minematsu K., Choki J., et al. Clinical and neuroradiological analysis of thrombotic and embolic cerebral infarction. Jpn Circ J 1984, 48:50-58.
159. Hornig C.R., Dorndorf W., Agnoli A.L. Hemorrhagic cerebral infarction: A prospective study. Stroke 1986, 17:179-185.
160. Okada Y., Yamaguchi T., Minematsu K., et al. Hemorrhagic transformation in cerebral embolism. Stroke 1989, 20:598-603.
161. Eisenberger H.M., Suddith R.L. Cerebral vessels have the capacity to transport sodium and potassium. Science 1979, 206:1083-1085.
162. Hart R.G. Cerebral Embolism Study Group: Timing of hemorrhagic transformation of cardioembolic stroke. Central nervous system control of the heart 1986, 229-232. Martinus Nijhoff Publishing, Boston. T. Stober, K. Schimrigk, D. Ganten (Eds.).
163. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: Brain hemorrhage and management options. Stroke 1984, 15:779-789.
164. Drake M.E., Shin C. Conversion of ischemic to hemorrhagic infarction by anticoagulant administration. Report of two cases with evidence from serial computed tomographic brain scans. Arch Neurol 1983, 40:44-46.
165. Meyer J.S., Gilroy J., Barnhart M.I., et al. Therapeutic thrombolysis in cerebral thromboembolism. Neurology 1963, 13:927-937.
166. Babikian V.L., Kase C.S., Pessin M.S., et al. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke 1989, 29:1500-1503.
167. Mori E., Tabuchi M., Yoshida T., et al. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988, 19:802-812.
168. del Zoppo G.J., Ferbert A., Otis S., et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke: A pilot study. Stroke 1988, 19:307-313.
169. Mori E., Yoneda Y., Tabuchi M., et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992, 42:976-982.
170. Hamann G.F., Okada Y., Fitridge R., et al. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995, 26:2120-2126.
171. International Stroke Trial Collaborative Group. The International Stroke Trial (IST) .: A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997, 349:1569-1681.
172. Chen Z.M., Sandercock P., Pan H.C., et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40,000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000, 31:1240-1249.
173. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997, 349:1641-1649.
174. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000, 31:601-609.
175. 3 during focal cerebral ischemia. J Cereb Blood Flow Metab 1999, 19:1038-1050.
176. UK-TIA Study Group. United Kingdom transient ischemic attack UK-TIA. aspirin trial: Interim results. Br Med J 1988, 296:316-320.
177. Diener H., Cunha L., Forbes C., et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
178. Kelton J.G. Antiplatelet agents: Rationale and results. Clin Haematol 1983, 12:311-354.
179. Harker L.A. Antiplatelet drugs in the management of patients with thrombotic disorders. Semin Thromb Hemost 1986, 12:134-155.
180. Fuster V., Badimon L., Badimon J., et al. Drugs interfering with platelet functions: Mechanisms and clinical relevance. Thrombosis and haemostesis 1987, 349-418. Leuven University Press, Leuven, Belgium. M. Verstraete, J. Vermylen, R. Lijnen, (Eds.).
181. Albers G.W., Amarenco P., Easton J.D., et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2000, 126:483S-512S.
182. del Zoppo G.J. Antithrombotic interventions in cerebrovascular disease. Thrombosis and hemorrhage 1998, 1279-1307. Williams and Wilkins, Baltimore. J. Loscalzo, A.I. Schafer (Eds.).
183. Easton J.D. Future perspectives for optimizing oral antiplatelet therapy. Cerebrovasc Dis 2001, 2:23-28.
184. Weksler B.B. Antiplatelet agents in stroke prevention, combination therapy: Present and future. Cerebrovasc Dis 2000, 5:41-48.
185. European Stroke Prevention Study Group. The European Stroke Prevention Study ESPS. Principal end-points. Lancet 1987, 2:1351-1354.
186. Bousser M.G., Eschwege E., Haguenau M., et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983, 14:5-14.
187. Crouse J.R., Byington R.P., Hoen H.M., et al. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997, 157:1305-1310.
188. Blauw G.J., Lagaay A.M., Smelt A.H.M., et al. Stroke, statins, and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997, 28:946-950.
189. Yoon S.S., Dambrosia J., Chalela J., et al. Rising statin use and effect on ischemic stroke outcome. BMC Med 2004, 2:4.
190. Vaughan C.J., Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999, 30:1969-1973.
191. Puccetti L., Bruni F., Di Renzo M., et al. Hypercoagulable state in hypercholesterolemic subjects assessed by platelet-dependent thrombin generation: In vitro effect of cerivastatin. Eur Rev Med Pharm Sci 1999, 3:197-204.
192. Roth G.J., Stanford N., Majerus P.W. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 1975, 72:3073-3076.
193. Preston F.E., Whipps S., Jackson C.A., et al. Inhibition of prostaglandin and platelet thromboxane A2 after low dose aspirin. N Engl J Med 1981, 304:76-79.
194. Clarke R.J., Mayo G., Price P., et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991, 325:1137-1141.
195. Baumgartner H.R., Tschopp T.B., Weiss H.J. Platelet interaction with collagen fibrils in flowing blood II. Impaired adhesion-aggregation in bleeding disorders. A comparison with subendothelium. Thromb Haemost 1977, 37:17-28.
196. Moake J.L., Turner N.A., Stathopoulos N.A., et al. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate and is resistant to aspirin. Blood 1988, 71:1366-1374.
197. Mundall J., Quintero P., von Kaulla K.N., et al. Transient monocular blindness and increased platelet aggregability treated with aspirin.
198. Harrison M.J.G., Marshall J., Meadows J.C., et al. Effect of aspirin in amaurosis fugax. Lancet 1971, 2:743-744.
199. Dyken M.L., Kolar O.J., Jones F.H. Differences in the occurrence of carotid transient ischemic attacks associated with antiplatelet aggregation therapy. Stroke 1973, 4:732-736.
200. Fields W.S., Lemak N.A., Frankowski R.F., et al. Controlled trial of aspirin in cerebral ischemia. Stroke 1977, 8:301-314.
201. Sorenson P.S., Pedersen H., Marquardsen J., et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish Cooperative Study. Stroke 1983, 14:15-22.
202. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978, 299:53-59.
203. Dutch TIA Trial Study Group. A comparison of two doses of aspirin 30 mg versus 283 mg a day in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991, 325:1261-1266.
204. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) . of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991, 338:1345-1349.
205. Fitzgerald G.A. Dipyridamole. N Engl J Med 1987, 316:1247-1257.
206. Hirsch L. Anticoagulant and platelet antiaggregant agents. Stroke: Pathophysiology, diagnosis and management 1986, Vol. 2:925-966. Churchill Livingston, New York. H.J. M. Barnett, J.P. Mohr, B.M. Stein (Eds.).
207. Harker L.A., Slichter S.J. Studies of platelet and fibrinogen kinetics in patients wtih prosthetic heart valves. N Engl J Med 1970, 283:1302-1305.
208. Ranhosky A. Dipyridamole letter. N Engl J Med 1987, 317:1734.
209. Acheson J., Danta G., Hutchinson E.C. Controlled trial of dipyridamole in cerebral vascular disease. Br Med J 1969, 1:614-615.
210. American-Canadian Cooperative Study Group. Persantine aspirin trial in cerebral ischemia. Part II. Endpoint results. Stroke 1985, 16:406-415.
211. Matias-Guiu J., Davalos A, Pico M., et al. Lowdose acetylsalicylic acid (ASA) . plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand 1987, 76:413-421.
212. ESPS-2 Working Group. Second European Stroke Prevention Study. J Neurol 1992, 239:299-301.
213. Wiley J.S., Chesterman C.N., Morgan F.J., et al. The effect of sulphinpyrazone on the aggregation and release reactions of human platelets. Thromb Res 1979, 14:23-33.
214. Evans G. Effect of drugs that suppress platelet surface interaction on incidence of amaurosis fugax and transient cerebral ischemia. Surg Forum 1972, 23:239-241.
215. Roden S., Low-Beer T., Carmalt M., et al. Transient cerebral ischemic attacks -Management and prognosis. Postgrad Med J 1981, 57:275-278.
216. Candelise L., Landi G., Perrone P., et al. A randomized trial of aspirin and sulfinpyrazone in patients with TIA. Stroke 1982, 13:175-179.
217. McTairoh D., Faulds D., Goa K.L. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990, 40:238-259.
218. Panak E., Maffrand J.P., Picard-Fraire C., et al. Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1983, 12(Suppl I):1-54.
219. Hass W.K., Easton J.D., Adams H.P., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for prevention of stroke in high-risk patients. N Engl J Med 1989, 321:501-507.
220. Gent M., Blakely J.A., Easton J.D., et al. The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989, 1:1215-1220.
221. Tsai H.M., Rice L., Sarode R., et al. Antibody inhibitors to von Willebrand factor metallogproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000, 132:794-799.
222. Bennett C.L., Davidson C.J., Raisch D.W., et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999, 159:2524-2538.
223. The European Stroke Prevention Study ESPS-2.Working Group Secondary stroke prevention: Aspirin/dypyridamole combination is superior to either agent alone and to placebo [abstract]. Stroke 1996, 27:195.
224. Britton M., Helmers C., Samuelsson K. Highdose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. Stroke 1987, 18:325-334.
225. Gent M., Blakeley J.A., Hachinski V., et al. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke 1985, 16:416-424.
226. Gryglewski R.J., Nowak S., Kostka-Trabka E., et al. Treatment of ischaemic stroke with prostacyclin. Stroke 1983, 14:197-202.
227. Huczynski J., Kostka-Trabka E., Sotowska W., et al. Double-blind controlled trial of the therapeutic effects of prostacyclin in patients with completed ischaemic stroke. Stroke 1985, 16:810-814.
228. Martin J.F., Hamdy N., Nicholl J., et al. Doubleblind controlled trial of prostacyclin in cerebral infarction. Stroke 1985, 16:386-390.
229. Bath P.M., Bath F.J. Prostacyclin and analogues for acute ischaemic stroke. Cochrane Database Syst Rev 2000, 2:CD000177.
230. Hsu C.Y., Faught R.E., Furlan A.J., et al. Intravenous prostacyclin in acute nonhemorrhagic stroke: A placebo-controlled double-blind trial. Stroke 1987, 18:352-358.
231. Bath P.M. Prostacyclin and analogues for acute ischaemic stroke. Cochrane Database Syst Rev computer file 2004, CD0001777.
232. Tanaka K., Gotoh F., Fukuuchi Y., et al. Stable prostacyclin analogue preventing microcirculatory derangement in experimental cerebral ischemia in cats. Stroke 1988, 19:1267-1274.
233. Steir C.T., Chander P.N., Belmonte A., et al. Beneficial action of beraprost sodium, a prostacyclin analog, in stroke-prone rats. J Cardiovasc Pharmacol 1997, 30:285-293.
234. Gurewich O., Lipinski B. Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole. Thromb Res 1976, 9:101-108.
235. Blakeley J.A. A prospective trial of sulfinpyrazone and survival after thrombotic stroke [abstract]. Thromb Haemost 1979, 42:382.
236. Herbert J.M., Frechel D., Vallee E., et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993, 11:180-198.
237. Savi P., Laplace M.C., Maffrand J.P., et al. Binding of [3H]-2-methylthio ADP to rat platelets: Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994, 269:772-777.
238. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events CAPRIE. Lancet 1996, 348:1329-1339.
239. Diener H.-C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, doubled-blind, placebo-controlled trial. Lancet 2004, 364:331-337.
240. Diener H.-C., Bogousslavsky J., Brass L.M., et al. Management of atherothrombosis with clopidogrel in highrisk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data. Cerebrovasc Dis 2004, 17:253-261.
241. Peters R.J., Mehta S.R., Fox K.A.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) . study. Circulation 2003, 108:1682-1687.
242. Mehta S.R., Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) . trial programme; Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000, 21:2033-2041.
243. Schror K. Antiplatelet drugs. A comparative review. Drugs 1995, 50:7-28.
244. Patient enrollment permanently discontinued in investigational clinical trial of ReoPro for acute ischemic stroke. October 28, 2005 http://www.centocor.com/news/news_103105.jsp.
245. Abciximab Emergent Stroke Treatment Trial AbESTT.Investigators Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of a randomized phase 2 trial. Stroke 2005, 36:880-890.
246. Qureshi A.I., Suri M.F., Khan J., et al. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: Preliminary experience. Neurosurgery 2000, 46:1316-1324.
247. Tong F.C., Cloft H.J., Joseph G.J., et al. Abciximab rescue in acute carotid stent thrombosis. Am J Neuroradiol 2000, 21:1750-1752.
248. Hofman R., Kerschner K., Steinwender C., et al. Abciximab bolus injection does not reduce cerebral iscemic complications of elective carotid artery stenting: A randomized study. Stroke 2002, 33:725-727.
249. Puccetti L., Pasqui A.L., Pastorelli M., et al. Timedependent effect of statins on platelet function in hypercholesterolemia. Eur J Clin Invest 2002, 32:901-908.
250. Schror K., Lobel P., Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids 1989, 2:39-45.
251. Serebruany V.L., Malinin A.I., Lowry D.R., et al. Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: A possible additional mechanism for clinical benefits. J Cardiovasc Pharmacol 2004, 43:677-684.
252. Northern American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991, 325:445-453.
253. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991, 337:1235-1243.
254. Harker L.A., Bernstein E.F., Dilley R.B., et al. Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy. Ann Intern Med 1992, 116:731-736.
255. Fields W.S., Lemak N.A., Frankowski R.F., et al. Controlled trial of aspirin in cerebral ischemia. Part II. Surgical group. Stroke 1978, 9:309-319.
256. Boysen G., Sorensen P.S., Juhler M., et al. Danish very low dose aspirin after carotid endarterectomy trial. Stroke 1988, 19:1211-1215.
257. Kretschmer G., Pratschner T., Prager M., et al. Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy. Ann Surg 1990, 211:317-322.
258. Pratschner T., Kretschmer G., Prager M., et al. Antiplatelet therapy following carotid bifurcation endarterectomy. Evaluation of a controlled clinical trial. Prognostic significance of histologic plaque examination on behalf of survival,. Eur J Vase Surg 1990, 4:285-289.
259. Harvald B., Hilden T., Lund E. Long-term anticoagulant therapy after myocardial infarction. Lancet 1962, 2:626-630.
260. Cooperative Study. Long-term anticoagulant therapy after myocardial infarction. JAMA 1965, 193:929-934.
261. Loeliger E.A., Hensen A., Kroes F., et al. A double blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1967, 182:549-567.
262. Breddin K., Loew D., Lechner K., et al. The German-Austrian Aspirin Trial: A comparison of acetylsalicyclic acid, placebo, and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980, 62(Supp l):V63-V72.
263. Sixty-Plus Reinfarction Study Research Group. A double-blind trial to assess long-term anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980, 2:989-994.
264. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990, 323:147-152.
265. Breddin K., Loew D., Lechner K., et al. Secondary prevention of myocardial infarction: A comparison of acetylsalicylic acid, placebo, and phenprocoumen. Haemostasis 1980, 9:325-344.
266. Hinton R.C., Kistler J.P., Fallon J.T., et al. Infl uence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol 1977, 40:509-513.
267. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987, 147:1561-1564.
268. Chesebro J.H., Fuster V., Halperin J.L. Atrial fibrillation-Risk marker for stroke. N Engl J Med 1990, 323:1556-1558.
269. Sherman D.A., Goldman L., Whiting R.B., et al. Thromboembolism in patients with atrial fibrillation. Arch Neurol 1984, 41:708-710.
270. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990, 322:863-868.
271. Petersen P., Boysen G., Godtfredsen J., et al. Placebo-controlled randomized trial of warfarin and aspirin to prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989, 1:175-179.
272. EAFT European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255-1262.
273. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: Analysis of pooled data from three randomized trials. Arch Intern Med 1997, 157:1237-1240.
274. Hart R.G., Benavente O., McBride R., et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999, 131:492-501.
275. Segal J.B., McNamara R.L., Miller M.R., et al. Prevention of thromboembolism in atrial fibrillation: A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med 2000, 15:56-67.
276. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994, 343:687-691.
277. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996, 348:633-638.
278. Gullov A.L., Koefoed B.G., Petersen P., et al. Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study: The AFASAK-2 study. Arch Intern Med 1998, 158:1513-1521.
279. Gullov A.L., Koefoed B.G., Petersen P. Bleeding during warfarin and asirin therapy in patients with atrial fibrillation: The AFASAK-2 Study. Arch Intern Med 1999, 159:1322-1328.
280. News Release: Plavix inferior to standard drug in stroke study. [Reuters] November 15, 2005.
281. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation. Chest 2004, 126:429S-456S.
282. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J 1964, 1:1209-1212.
283. Levine H.J., Pauker S.G., Salzman E.W. Antithrombotic therapy in valvular heart disease. Chest 1989, 95:98S-106S.
284. Salem D.N., Stein P.D., Al-Ahmad A., et al. Anti thrombotic therapy in valvular heart disease -native and prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:457S-482S.
285. Coulshed N., Epstein E.J., McKendrick C.S., et al. Systemic embolism in mitral valve disease. Br Med J 1970, 32:26-34.
286. Kopf G.S., Hammond G.L., Geha A.S., et al. Long-term performance of the St. Jude medical valve: Low incidence of thromboembolism and hemorrhagic complications with modest doses of warfarin. Circulation 1987, 76:132-136. (Suppl).
287. Barnhorst D.A., Oxman H.A., Connolly D.C., et al. Long-term follow-up of isolated replacement of the aortic or mitral valve with the Starr-Edwards prosthesis. Am J Cardio 1975, 35:228-233.
288. Turpie A.G.G., Gunstensen J., Hirsh J., et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve placement. Lancet 1988, 1:1242-1245.
289. Turpie A.G.G., Gent M., Laupacis A., et al. Comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993, 329:524-529.
290. Loeliger E.A., Poller L., Samama M., et al. Questions and answers on prothrombin time standardization in oral anticoagulant control. Thromb Haemost 1985, 54:515-517.
291. Loeliger E.A. Therapeutic target values in oral anticoagulation-Justification of Dutch policy and a warning against the so-called moderate-intensity regimens. Ann Hematol 1992, 64:60-65.
292. Dale J., Myhre E., Storstein O., et al. Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves. Am Heart J 1977, 94:101-111.
293. Altman R., Boullon F., Rouvier J., et al. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976, 72:127-129.
294. Sullivan J.M., Harken D.E., Gorlin R. Effect of dipyridamole on the incidence of arterial emboli after cardiac valve replacement. Circulation 1969, 39/40:I.
295. Sullivan J.M., Harken D.E., Gorlin R. Pharmacologic control of thromboembolic complications of cardiac valve replacement. N Engl J Med 1971, 284:1391-1394.
296. Pouleur H., Buyse M. Effects of dipyridamole in comobination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves: A meta-analysis of the randomized trials. J Thorac Cardiovasc Surg 1995, 110:463-472.
297. Nuñez L., Aguado M.G., Celemin D., et al. Aspirin or coumadin as the drug of choice for valve replacement with porcine bioprosthesis. Ann Thorac Surg 1982, 33:355-358.
298. Nuñez L., Aguado M.G., Larrea J.L., et al. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg 1984, 37:84-87.
299. Hoogendijk E.M., Jenkins C.S., van Wijk E.M., et al. Spontaneous platelet aggregation in cerebrovascular disease. II. Further characterisation of the platelet defect. Thromb Haemost 1979, 41:512-522.
300. Fisher M., Levine P.H., Fullerton A.L., et al. Marker proteins of platelet activation in patients with cerebrovascular disease. Arch Neurol 1982, 39:692-695.
301. Taomoto K., Asada M., Kanazawa Y., et al. Usefulness of the measurement of plasma beta-thromboglobulin beta-TG in cerebrovascular disease. Stroke 1983, 14:518-524.
302. Landi G., D'Angelo A., Boccardi E., et al. Hypercoagulability in acute stroke: Prognostic significance. Neurology 1987, 37:1667-1671.
303. Fisher M., Francis R. Altered coagulation in cerebral ischemia, platelet, thrombin, and plasmin activity. Arch Neurol 1990, 47:1075-1079.
304. Feinberg W.M. Coagulation. Brain ischemia. Basic concepts and clinical relevance 1995, 85-96. Springer- Verlag, Berlin, Heidelberg, New York. L.R. Caplan (Ed.).
305. Couch J.R., Hassanein R.S. Platelet aggregation, stroke, and transient ischemic attack in middle-aged and elderly patients. Neurology 1976, 26:888-895.
306. Candelise L., Landi G., Perrone P., et al. A randomized trial of aspirin and sulfinpyrazone in patients with TIA. Stroke 1982, 13:175-179.